Stocktaking: Lancet Research Selection sq., May 2, 2020

4-price dengue vaccine TAK-003 II Clinical Effects StudyDOI: https://doi.org/10.1016/S0140-6736 (20)305 56-0universally applicable quaddrug vaccine remains a major challenge, and researchers recently assessed the immunogenicity and safety of three different dose combinations of tetravalent dengue vaccine (tak-003) for children living in countries where dengue fever is endemic within 48 monthsthis study was a Phase II clinical study in which healthy participants aged 2-17 received 2 doses of tak-003 (day 1 and 91), 1 dose of tak-003 (day 1), 1 dose of tak-003 plus a synergizer (day 1 and 365 days) or placebo, respectivelyThe main purpose of the study was to assess the geometric average titer of various serotype antibodies in the 48th month of each programmeSecondary safety endpoints include the proportion of participants with severe adverse events and symptoms that are virologically confirmed in dengue1,800 children participated in the study, of whom 201 were in the 1 dose vaccination group, 398 in the 1 dose vaccination group, 1002 in the 1 dose of inoculation and synergist group, 199 in the placebo group and 1,479 (82%) of the participants completed the 48-month studyAt the 48th month, antibody titer in all TAK-003 groups remained elevated compared to the placebo group, regardless of baseline serum statusIn the 48th month, the geometric average titer in the DENV1 subtype 2 dose group was 378, the 1 dose group was 421, the 1 dose plus the synergizer group was 719, and the placebo group was 100The average titer of DENV2 subtype geometry was 1052, 1319, 1200 and 208, respectivelyDENV3 subtypes are: 183, 201, 288 (and 71)DENV4 subtypes are: 152, 164, 219 and 46The four-price serum-positive rates were 89%, 86%, 97% and 60%, respectivelyThirty-seven (2%) TAK-003 and 13 (7%) placebo group participants recorded virologically confirmed dengue fever with a relative risk of 0.35No serious adverse events or severe dengue virus diseases associated with vaccines have been reported2, phase 4 efficacy assessment of the dengue vaccine TAK-003 III DOI: https://doi.org/10.1016/S0140-6736 (20) 30414-1 -disease vaccine, especially for children, is still one of the hot spots in research and development, and researchers recently evaluated the efficacy, safety and immunity of quadripartite dengue-reduced live vaccine (TAK-003) for healthy children aged 4-16 years old this study was phase III clinical studies, healthy children aged 4-16 years were randomly inoculated with two doses of TAK-003 or two doses of placebo, 3 months apart, follow-up period of up to 18 months after vaccination, and viral dengue dengue fever (VCD) testing of fever patients by serotype-specific RT-PCR 2099 participants Statistics showed that the vaccine effectiveness rate was 80.2%, 61 cases of VCD patients in the TAK-003 group and 149 in the placebo group In the secondary endpoint assessment, the total vaccine effectiveness was 73.3 per cent The secondary endpoint analysis showed that the effective rate of baseline serologically positive patients was 76.1%, the effective rate of baseline serologically negative patients was 66.2%, the effective rate for inpatient dengue fever was 90.4%, and the effective rate for dengue haemorrhagic fever was 85.9% There were serological differences in efficacy, with THE EFFECTIVE RATE OF DENV1 being 69.8%, the DENV2 type being 95.1%, the DENV3 type being 48.9% and the DENV4 type being 51.0% The rate of severe adverse events between groups is comparable (4.0 vs 4.8%), and infection is the most common adverse event the renal de-neurosurgery, the antihypertensive effect does not require drug maintenance DOI: https://doi.org/10.1016/S0140-6736 (20) 30554-7 previous studies have shown that catheter-based renal deneurals can significantly reduce blood pressure In the SPYRAL Pivotal study, researchers assessed the efficacy of renal de-neurosis without antihypertensive drugs Patients with hypertension with blood pressure of 150-180mmHg in the clinic were randomly given renal de-neurosis or simulated surgery The main end point of efficacy in the study was the change of systolic pressure after baseline adjustment 24 hours, and the secondary end of efficacy was the change of baseline-adjusted outpatient systolic pressure from baseline to 3 months after surgery 331 patients participated in the study, randomly divided into renal loss nerve group (n-166) and simulated surgical group (n-165) The renal loss nerve group reached the end of primary and secondary efficacy, and the probability of renal loss of neurooperative efficacy was greater than 0.999 The difference in treatment of 24-hour systolic pressure was -3.9mmHg and the difference between outpatient systolic pressure was -6.5mmHg No major security incidents occurred in 3 months Source: MedSci Original